Bascule Biosciences, Inc. filed a Form D with the Securities and Exchange Commission on 2026-04-02.
Bascule Biosciences, Inc. filed a Form D notice of an exempt securities offering with the SEC on April 2, 2026. The filing reports $250K sold. Its industry group is Biotechnology. It names Aafia Chaudhry (Executive Officer, Director) (SEC Form D, April 2, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Bascule Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-04-02 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Bascule Biosciences, Inc.
Free to see. No signup.
More on the people and the money behind Bascule Biosciences, Inc., from the filings we hold.
Biotechnology raises by companies based in New York, filed within 90 days of this one, largest first.
Get an email when Bascule Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Bascule Biosciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch Bascule Biosciences, Inc. →Get the full cited report on Bascule Biosciences, Inc.
What the filing shows about Bascule Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bascule Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Bascule Biosciences, Inc.'s address as 155 Stratton Road, New Rochelle, NY 10804.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Bascule Biosciences, Inc. See pricing
Bascule Biosciences, Inc. is a registered filer with the SEC (CIK 2126807) and has filed since 2026-04-02. 1 filing is on record, the latest on 2026-04-02.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Bascule Biosciences, Inc.'s Form D of 2026-04-02 names Aafia Chaudhry as its officers, directors or promoters.
Its new offerings report $250K sold across 1 offering, as its own filings state.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $250K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Aafia Chaudhry is named as Executive Officer and Director on the Form D that Bascule Biosciences, Inc. filed with the SEC on 2 April 2026, the only person that filing names.
1 person named on the filing — 1 holding an executive role.
Named as of the 2026-04-02 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about Bascule Biosciences, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bascule Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bascule Biosciences, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Bascule Biosciences, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Bascule Biosciences, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Bascule Biosciences, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in New York
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/bascule-biosciences-inc-form-d-26000002